Physician profile
Andrea E Gunnells
NPI 1174588024
$13,093.20
in general payments reported to CMS, 2019-2025
42 companies · $2,496 in 2025
The $2,496 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,089 · 2022: $2,927 · 2023: $2,468 · 2024: $2,113 · 2025: $2,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,077.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,279.78 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,006.18 | 2021 | |
| Ucb, INC. | $994.62 | 2021-2025 | Nayzilam, Fintepla, Briviact |
| Livanova USA, INC. | $933.23 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $887.97 | 2021-2025 | Ajovy |
| Pfizer INC. | $515.89 | 2023-2025 | |
| Lilly USA, LLC | $497.51 | 2021-2025 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $455.62 | 2022 | |
| Lundbeck LLC | $439.88 | 2021-2025 | Vyepti |
| Impel Pharmaceuticals INC. | $393.14 | 2022-2023 | Trudhesa |
| Amgen INC. | $391.10 | 2021-2023 | Aimovig |
| Sk Life Science, INC. | $359.40 | 2022-2025 | Xcopri |
| Scilex Pharmaceuticals INC. | $333.38 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $287.91 | 2023-2024 | Nuedexta |
| Upsher-Smith Laboratories LLC | $242.32 | 2021-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $210.51 | 2022-2024 | Onzetra Xsail, Contrave |
| Novartis Pharmaceuticals Corporation | $187.88 | 2021 | |
| Jazz Pharmaceuticals INC. | $172.64 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $159.08 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $137.48 | 2023-2024 | Daybue |
| Springworks Therapeutics, INC. | $110.15 | 2025 | Gomekli |
| Octapharma USA, INC. | $103.40 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Axsome Therapeutics, INC. | $98.88 | 2025 | Symbravo |
| Biogen, INC. | $98.78 | 2022-2025 | Spinraza |
| Amneal Pharmaceuticals LLC | $90.65 | 2023 | Lyvispah |
| Abbott Laboratories | $89.94 | 2022-2023 | Infinity |
| Supernus Pharmaceuticals, INC. | $71.42 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $71.27 | 2023-2024 | Fycompa |
| Ge Healthcare | $70.50 | 2021-2023 | |
| Neurelis, INC. | $59.09 | 2021-2025 | Valtoco |
| Allergan, INC. | $56.40 | 2021 | |
| Impel Pharmaceuticals LLC | $54.20 | 2024-2025 | Trudhesa |
| Collegium Pharmaceutical, INC. | $47.73 | 2022 | |
| Alexion Pharmaceuticals, INC. | $36.03 | 2022-2025 | Koselugo |
| Csl Behring | $35.80 | 2025 | Hizentra |
| Biomarin Pharmaceutical INC. | $28.67 | 2025 | Brineura |
| Ipsen Biopharmaceuticals, INC | $16.72 | 2021 | |
| Cranial Technologies, INC | $16.47 | 2025 | Doc Band |
| Harmony Biosciences LLC | $16.32 | 2023 | Wakix |
| Tonix Medicines, INC. | $15.77 | 2024 | Zembrace Symtouch |
| Sunovion Pharmaceuticals INC. | $12.62 | 2022 | |
| Sumitomo Pharma America, INC. | $6.87 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Gunnells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.